El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Novartis AG
Cerrado
153.09 -0.73
Resumen
Variación precio
24h
Mínimo
153
Máximo
154.5
Ingresos | -1.5B 2.4B |
|---|---|
Ventas | -1B 13B |
P/B Media del Sector | 22.768 61.417 |
BPA | 2.03 |
Rentabilidad por dividendo | 2.93 |
Margen de beneficio | 18.064 |
Empleados | 75,267 |
EBITDA | -769M 5.1B |
Recomendaciones | Neutral |
|---|---|
Estimación a 12 meses | +8.84% upside |
Rentabilidad por dividendo Media del Sector | 2.93% 2.40% |
|---|
Capitalización de Mercado | 25B 315B |
|---|---|
Apertura anterior | 153.82 |
Cierre anterior | 153.09 |
Puntuación técnica
By Trading Central
Confianza
Bearish Evidence
Novartis AG Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Novartis AG Esperado
Precio Objetivo
By TipRanks
8.84% repunte
Estimación a 12 meses
Media 167 USD 8.84%
Máximo 180 USD
Mínimo 141 USD
De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novartis AG Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Novartis AG
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Live chat